WASHINGTON — The libertarian think tank behind the federal “right-to-try” law is back at it again.
Its new legislation, which became law in Arizona on Monday, is meant to speed patients’ access to bespoke treatments that target issues with patients’ own genomes. It focuses on more experimental drugs than the first right-to-try laws, which let dying patients access drugs that had cleared early clinical trials without the blessing of the Food and Drug Administration.
Create a display name to comment
This name will appear with your comment